Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xeris Biopharma Holdings (XERS) Other Non-Current Assets: 2020-2025

Historic Other Non-Current Assets for Xeris Biopharma Holdings (XERS) over the last 4 years, with Sep 2025 value amounting to $5.3 million.

  • Xeris Biopharma Holdings' Other Non-Current Assets fell 2.31% to $5.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.3 million, marking a year-over-year decrease of 2.31%. This contributed to the annual value of $5.4 million for FY2024, which is 19.10% up from last year.
  • According to the latest figures from Q3 2025, Xeris Biopharma Holdings' Other Non-Current Assets is $5.3 million, which was up 5.04% from $5.1 million recorded in Q2 2025.
  • Xeris Biopharma Holdings' Other Non-Current Assets' 5-year high stood at $5.5 million during Q2 2024, with a 5-year trough of $211,000 in Q3 2021.
  • Moreover, its 3-year median value for Other Non-Current Assets was $5.1 million (2025), whereas its average is $5.0 million.
  • Its Other Non-Current Assets has fluctuated over the past 5 years, first surged by 928.44% in 2022, then fell by 7.86% in 2025.
  • Quarterly analysis of 5 years shows Xeris Biopharma Holdings' Other Non-Current Assets stood at $829,000 in 2021, then skyrocketed by 470.57% to $4.7 million in 2022, then decreased by 4.02% to $4.5 million in 2023, then rose by 19.10% to $5.4 million in 2024, then decreased by 2.31% to $5.3 million in 2025.
  • Its Other Non-Current Assets was $5.3 million in Q3 2025, compared to $5.1 million in Q2 2025 and $5.1 million in Q1 2025.